Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells.
bardoxolone-methyl
heme oxygenase-1
oral squamous cell carcinoma
radiotherapy
reactive oxygen species
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
09
2020
accepted:
09
12
2020
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
epublish
Résumé
Radiotherapy represents a common treatment strategy for patients suffering from oral squamous cell carcinoma (OSCC). However, application of radiotherapy is immanently limited by radio-sensitivity of normal tissue surrounding the tumor sites. In this study, we used normal human epithelial keratinocytes (NHEK) and OSCC cells (Cal-27) as models to investigate radio-modulating and anti-tumor effects of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9,-dien-28-oic acid methyl ester (CDDO-Me). Nanomolar CDDO-Me significantly reduced OSCC tumor xenograft-growth
Identifiants
pubmed: 33584286
doi: 10.3389/fphar.2020.607580
pii: 607580
pmc: PMC7878525
doi:
Types de publication
Journal Article
Langues
eng
Pagination
607580Informations de copyright
Copyright © 2021 Hermann, Lang, Popp, Hafner, Steinritz, Rump, Port and Eder.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor DR declared a past co-authorship with one of the authors MP.
Références
PLoS One. 2011 Mar 25;6(3):e18148
pubmed: 21464958
Integr Cancer Ther. 2004 Dec;3(4):294-300
pubmed: 15523100
Clin Cancer Res. 2013 Aug 15;19(16):4309-14
pubmed: 23719265
Radiat Res. 2013 Sep;180(3):259-67
pubmed: 23919312
Neoplasia. 2018 Mar;20(3):227-232
pubmed: 29448084
Cancer Res. 2005 Jun 1;65(11):4789-98
pubmed: 15930299
PLoS One. 2014 Dec 23;9(12):e115600
pubmed: 25536195
Cancers (Basel). 2019 Oct 17;11(10):
pubmed: 31627329
J Radiat Res. 2016 Sep;57(5):567-571
pubmed: 27242339
Am J Physiol Regul Integr Comp Physiol. 2017 Dec 1;313(6):R646-R653
pubmed: 28835450
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2949-55
pubmed: 23045680
Front Pharmacol. 2012 Mar 14;3:45
pubmed: 22457648
Antioxidants (Basel). 2017 May 05;6(2):
pubmed: 28475131
J Clin Invest. 1999 Jan;103(1):129-35
pubmed: 9884342
Adv Sci (Weinh). 2018 Jun 14;5(8):1701036
pubmed: 30128225
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
J Dent Res. 2018 Jun;97(6):635-644
pubmed: 29489434
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4584-9
pubmed: 15767573
Cancer Chemother Pharmacol. 2017 Feb;79(2):295-301
pubmed: 27942929
Oncotarget. 2016 Aug 9;7(32):50814-50815
pubmed: 27449104
Radiat Oncol. 2012 Jan 17;7:4
pubmed: 22247972
Environ Mol Mutagen. 2015 Jul;56(6):491-504
pubmed: 25773265
Sci Rep. 2017 May 03;7:46690
pubmed: 28466861
Radiat Res. 2006 Jul;166(1 Pt 2):271-86
pubmed: 16808613
Am J Nephrol. 2018;47(1):40-47
pubmed: 29402767
Am J Pathol. 2004 Sep;165(3):1045-53
pubmed: 15331427
J Biol Chem. 2007 Jul 13;282(28):20621-33
pubmed: 17430897
Pharmacol Rev. 2012 Oct;64(4):972-1003
pubmed: 22966038
Drug Des Devel Ther. 2014 Oct 23;8:2075-88
pubmed: 25364233
Molecules. 2019 Nov 13;24(22):
pubmed: 31766211
Int J Mol Sci. 2019 Oct 28;20(21):
pubmed: 31661901
Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006387
pubmed: 21154367
Oxid Med Cell Longev. 2013;2013:639541
pubmed: 24101950